New Delhi-based leg care brand, Varco Leg Care, has successfully raised $0.5 million (over Rs 4.5 crore) in seed funding, marking a significant achievement in its growth trajectory.

The funding round, concluded recently, has propelled the company's valuation to double within just 10 months. The seed funding was led by Sunicon Maiden Fund, an early-stage venture fund managed by Sunicon Ventures.

Varco Leg Care plans to deploy the newly acquired seed capital strategically to enhance its capabilities across various fronts.

This includes bolstering offline touchpoints, advancing research and development (R&D) initiatives, and scaling and optimizing marketing efforts.

Additionally, the company aims to allocate substantial funds and resources towards strengthening its credibility through the expansion of its existing IP portfolio, with four patents already filed by Varco. Furthermore, Varco intends to publish findings from its in-house conducted clinical studies in reputable medical journals.

Anondeep Ganguly, CEO of Varco Leg Care, expressed elation regarding the latest fundraise, emphasizing the vote of confidence shown by Sunicon Maiden Fund in Varco's innovative approach to leg health management. Ganguly highlighted that the capital infusion represents a significant milestone in Varco's growth journey, enabling the company to expand its customer base, supply chain, and offline visibility. Moreover, the funding will play a pivotal role in advancing Varco's commitment to providing robust, evidence-based research and solutions for leg health management. Ganguly emphasized Varco's focus on extensive clinical trials and its utilization of pioneering low-friction technology to establish and validate evidence for its solutions.

Moving forward, Varco Leg Care remains dedicated to delivering top-notch leg health solutions while prioritizing the needs of its customers at the core of its R&D initiatives. As the company continues to grow and scale, it remains committed to upholding its mission of enhancing leg health through innovative and evidence-based solutions.